Secondary endpoints included an assessment of whether patients who were treated with Ostarine had any improvement in their quality of life, or if they required less healthcare resources than the placebo group. While the trial was a failure overall, the positive takeaway was that Enobosarm (Ostarine) demonstrated significant quantitative advantage in LBM (lean body mass) compared to placebo in both trials [R], chemyo products. In layman's terms, Ostarine on average increased or maintained a significantly greater amount of muscle mass in the patients that were treated with it, relative to those who were treated with placebo. Following that, in 2016 GTx started a phase II clinical trial to assess Ostarine's viability as a stress urinary incontinence treatment for women. The results of that did not achieve statistical significance [R].While most individuals who use Ostarine (MK2866) don't experience many side effects, there are some rare cases where they may occur, chemyo products.